Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDexmedetomidine hydrochloride
Description: Potent, highly selective α2 agonist. Active isomer of medetomidine (Cat. No. 5160)
Alternative Names: d-Medetomidine hydrochloride
Chemical Name: 4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride
Purity: ≥98%
Biological Activity for Dexmedetomidine hydrochloride
Dexmedetomidine hydrochloride is an active isomer of medetomidine, a potent, highly selective α2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively). Displays greater selectivity over α1-adrenoceptors than Clonidine (Cat. No. 0690) and UK 14,304 (1620-, 220- and 300-fold respectively). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects.
Racemate also available.
Compound Libraries for Dexmedetomidine hydrochloride
Dexmedetomidine hydrochloride is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
Technical Data for Dexmedetomidine hydrochloride
| M. Wt | 236.74 |
| Formula | C13H16N2.HCl |
| Storage | Desiccate at RT |
| Purity | ≥98% |
| CAS Number | 145108-58-3 |
| PubChem ID | 6918081 |
| InChI Key | VPNGEIHDPSLNMU-MERQFXBCSA-N |
| Smiles | C[C@H](C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Dexmedetomidine hydrochloride
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 23.67 | 100 | |
| DMSO | 23.67 | 100 |
Preparing Stock Solutions for Dexmedetomidine hydrochloride
The following data is based on the product molecular weight 236.74. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.22 mL | 21.12 mL | 42.24 mL |
| 5 mM | 0.84 mL | 4.22 mL | 8.45 mL |
| 10 mM | 0.42 mL | 2.11 mL | 4.22 mL |
| 50 mM | 0.08 mL | 0.42 mL | 0.84 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Dexmedetomidine hydrochloride
References for Dexmedetomidine hydrochloride
References are publications that support the biological activity of the product.
Virtanen et al (1988) Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist. Eur.J.Pharmacol. 150 9 PMID: 2900154
Fisher et al (1991) Antinociceptive properties of intrathecal dexmedetom. in rats. Eur.J.Pharmacol. 192 221 PMID: 1674472
Scheinin et al (1989) Medetomidine - a novel α2-adrenoceptor agonist: a review of its pharmacodynamic effects. Prog.Neuro-Psychopharm.Biol.Psychiat. 13 635 PMID: 2571177
If you know of a relevant reference for Dexmedetomidine hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Dexmedetomidine hydrochloride, Dexmedetomidine hydrochloride supplier, Active, isomer, α2-Adrenergic, alpha2-Adrenergic, Receptors, α2-adrenoceptor, alpha2-adrenoceptors, a2-adrenoceptors, a2-adrenergic, d-Medetomidine, hydrochloride, Adrenergic, Alpha-2, 2749, Tocris Bioscience
7 Citations for Dexmedetomidine hydrochloride
Citations are publications that use Tocris products. Selected citations for Dexmedetomidine hydrochloride include:
Yuki et al (2011) Sedative drug modulates T-cell and lymphocyte function-associated antigen-1 function. Anesth Analg 112 830 PMID: 21385989
Uchida et al (2019) Induction of Non-Apoptotic Cell Death by Adrenergic Agonists in Human Oral Squamous Cell Carcinoma Cell Lines. Anticancer Res 39 3519 PMID: 31262876
Rennekamp et al (2016) σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol 12 552 PMID: 27239788
Gozzi et al (2013) Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine. Neuropsychopharmacology 38 2120 PMID: 23736277
Ma et al (2019) Galanin Neurons Unite Sleep Homeostasis and α2-Adrenergic Sedation Curr Biol 29 3315 PMID: 31543455
Garrity et al (2015) Dexmedetomidine-induced sedation does not mimic the neurobehavioral phenotypes of sleep in Sprague Dawley rat. Invest Ophthalmol Vis Sci 38 73 PMID: 25325438
McAlvin et al (2015) Corneal Anesthesia With Site 1 Sodium Channel Blockers and dexmedetom. J Inflamm (Lond) 56 3820 PMID: 26066750
Do you know of a great paper that uses Dexmedetomidine hydrochloride from Tocris? Please let us know.
Reviews for Dexmedetomidine hydrochloride
There are currently no reviews for this product. Be the first to review Dexmedetomidine hydrochloride and earn rewards!
Have you used Dexmedetomidine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.